Memantine (Namenda) for moderate to severe Alzheimer's disease

被引：0

作者：

Ables, AZ ^{[1
]}

机构：

[1] Spartanburg Family Med Residency Program, Spartanburg, SC USA

来源：

AMERICAN FAMILY PHYSICIAN | 2004年 / 69卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Synopsis: Memantine (Namenda) is an N-methyl-d-aspartate'(NMDA) receptor blocker indicated for the treatment of moderate to severe Alzheimer's disease (AD). The NMDA receptor is activated by glutamate, the primary excitatory neurotransmitter in the brain. Overstimulation by glutamate may result in neuronal damage and has been implicated in neurodegenerative disorders such as AD. Memantine is the first pharmacologic agent approved by the US. Food and Drug Administration for the treatment of moderate to severe AD.

引用

页码：1491 / 1492

页数：2

共 5 条

[1]

[Anonymous], 2003, MED LETT DRUGS THER, V45, P73

[2]

AREOSA SA, 2003, COCHRANE DATABASE SY

[3] Memantine in moderate-to-severe Alzheimer's disease [J].

Reisberg, B ;

Doody, R ;

Stoffler, A ;

Schmitt, F ;

Ferris, S ;

Mobius, HJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1333-1341

[4] Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial [J].

Tariot, PN ;

Farlow, MR ;

Grossberg, GT ;

Graham, SM ;

McDonald, S ;

Gergel, I .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (03) :317-324

[5]

2004, FACTS MEMANTINE EXPT

← 1 →